Successful Etanercept Therapy in Therapy-Refractory Acrodermatitis Continua Suppurativa Hallopeau

A 50-year-old patient with acrodermatitis continua suppurativa Hallopeau, who did not respond to various topical treatments and systemic acitretin, experienced significant improvement with etanercept therapy. Initial treatments included glucocorticosteroids, calcitriol, calcipotriol, tacrolimus, and bath-PUVA, which were ineffective. Systemic acitretin improved symptoms but caused mucosal side effects and hair loss, leading to dose reduction and disease flare. Etanercept 2 x 25 mg subcutaneously weekly resolved all symptoms within four weeks, including joint pain and nail growth. After six months, discontinuation of etanercept led to a rebound of pustules, but reintroduction of the therapy cleared symptoms rapidly. This case suggested that etanercept could be an effective treatment for refractory acrodermatitis continua suppurativa Hallopeau.